Skip to main content
Clinical Trials/NCT05049980
NCT05049980
Completed
Not Applicable

Evaluation of the Efficacy, Tolerance of the Treatment, and Patient Satisfaction During the Management of an Arrested Pregnancy in the First Trimester According to the New Toulouse University Hospital Protocol

University Hospital, Toulouse1 site in 1 country52 target enrollmentNovember 1, 2021

Overview

Phase
Not Applicable
Intervention
Medical treatment with Mifégyne® and MisoOne®
Conditions
Pregnancy Loss, Early
Sponsor
University Hospital, Toulouse
Enrollment
52
Locations
1
Primary Endpoint
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The clinical practice recommendations highlight the fact that the patient's choice concerning the management of her aborted pregnancy in the first trimester should be privileged, after clear and appropriate information on the available treatments, in order to improve his experience and reduce the negative psychological symptoms that can generate an alteration in the quality of life, in the aftermath of the loss of pregnancy.

The present study will describe the efficacy, satisfaction and tolerance of patients benefiting from medical treatment with Mifégyne® and MisoOne® versus those benefiting from surgical treatment by endo-uterine aspiration for the management of a pregnancy stopped during the first trimester at the Toulouse University Hospital

Registry
clinicaltrials.gov
Start Date
November 1, 2021
End Date
February 14, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Any adult patient presenting to the gynecological emergency department of the Paule de Viguier Hospital in Toulouse for whom a diagnosis of an arrested pregnancy in the first trimester is made
  • Whose cranio-caudal length of the embryo measured by ultrasound is less than 25 mm or having a clear egg
  • Having agreed to the study (written or verbal) after clear and fair information
  • Who understands and reads French

Exclusion Criteria

  • Medical contraindication to treatment with Mifégyne® or MisoOne®
  • Hemodynamically unstable patient requiring urgent surgical treatment.
  • Protected adult patient (guardianship, curatorship, safeguard of justice)

Arms & Interventions

Medical treatment

Patients choosing medical treatment with Mifégyne® and MisoOne®

Intervention: Medical treatment with Mifégyne® and MisoOne®

Surgical treatment

Patients choosing surgical treatment by endo-uterine aspiration.

Intervention: Endo-uterine aspiration

Outcomes

Primary Outcomes

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time Frame: Inclusion day (day 0)

Patient satisfaction

Time Frame: Inclusion day (day 0)

Completing the satisfaction questionnaire

Study Sites (1)

Loading locations...

Similar Trials